Understanding the biological basis of RCC has led to the development of new targeted agents, including immune checkpoint inhibitors, vascular endothelial growth factor receptor (VEGFR) inhibitors, tyrosine kinase inhibitors (TKIs), and mammalian target of rapamycin (mTOR) inhibitors [3–8]. The gene discussed is KDR; the disease is renal cell carcinoma.